Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HMGCR | P04035 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6747785 | 1.00 | THRB (0.43) | THRBALOX15HMGCRSMN1; SMN2 | |
| SCHEMBL4446005 | 0.84 | THRB (0.41) | THRBALOX15HMGCRSMN1; SMN2 | |
| SCHEMBL10326025 | 0.84 | THRB (0.41) | THRBALOX15HMGCRSMN1; SMN2 | |
| SCHEMBL2217512 | 0.84 | THRB (0.41) | THRBALOX15HMGCRSMN1; SMN2 | |
| SCHEMBL22767233 | 0.82 | SMN1; SMN2 (0.38) | THRBALOX15HMGCRSMN1; SMN2 | |
| SCHEMBL14079300 | 0.82 | SMN1; SMN2 (0.38) | THRBALOX15HMGCRSMN1; SMN2 | |
| SCHEMBL6747790 | 0.81 | SMN1; SMN2 (0.39) | THRBALOX15SMN1; SMN2 | |
| SCHEMBL11355194 | 0.77 | HMGCR (0.38) | HMGCR | |
| SCHEMBL22767512 | 0.77 | HMGCR (0.36) | THRBALOX15HMGCRSMN1; SMN2 | |
| SCHEMBL10046539 | 0.76 | SMN1; SMN2 (0.34) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8471045-B2 | Synthesis of statins | LEK PHARMACEUTICALS D.D. (SI) | 2013-06-25 | — | — | US | disclosed |
| US-20120196333-A1 | SYNTHESIS OF STATINS | LEK PHARMACEUTICALS D.D. (SI) | 2012-08-02 | — | — | US | disclosed |
| US-8183397-B2 | Synthesis of statins | LEK PHARMACEUTICALS D.D. (SI) | 2012-05-22 | — | — | US | disclosed |
| US-20110178295-A1 | SYNTHESIS OF STATINS | LEK PHARMACEUTICALS D.D. (SI) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178295-A1 | SYNTHESIS OF STATINS | HMGCR, DHCR7, COASY | THRB 3024/4885ALOX15 627/4885HMGCR 1/4885 |
| US-20120196333-A1 | SYNTHESIS OF STATINS | HMGCR, DHCR7, COASY | THRB 3024/4885ALOX15 627/4885HMGCR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.